In Vitro Studies of Antiphospholipid Antibodies and Its Cofactor, β2-Glycoprotein I, Show Negligible Effects on Endothelial Cell Mediated Protein C Activation

Janine D Oosting; Ronald H W M Derksen; Tilman M Hackeng; Marja van Vliet; Klaus T Preissner; Bonno N Bouma; Philip G de Groot

doi:10.1055/s-0038-1646483

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1991; 66(06): 666-671
DOI: 10.1055/s-0038-1646483

Original Article

Schattauer GmbH Stuttgart

In Vitro Studies of Antiphospholipid Antibodies and Its Cofactor, β₂-Glycoprotein I, Show Negligible Effects on Endothelial Cell Mediated Protein C Activation

Janine D Oosting

¹The Department of Haematology, University Hospital Utrecht, Utrecht, The Netherlands

²The Department of Internal Medicine (Division of Immunopathology), University Hospital Utrecht, Utrecht, The Netherlands

,

Ronald H W M Derksen

²The Department of Internal Medicine (Division of Immunopathology), University Hospital Utrecht, Utrecht, The Netherlands

,

Tilman M Hackeng

¹The Department of Haematology, University Hospital Utrecht, Utrecht, The Netherlands

,

Marja van Vliet

¹The Department of Haematology, University Hospital Utrecht, Utrecht, The Netherlands

²The Department of Internal Medicine (Division of Immunopathology), University Hospital Utrecht, Utrecht, The Netherlands

,

Klaus T Preissner

The Department of Haemostasis Research, Max Planck Gesellschaft, Bad Nauheim, Federal Republic of Germany

,

Bonno N Bouma

¹The Department of Haematology, University Hospital Utrecht, Utrecht, The Netherlands

,

Philip G de Groot

¹The Department of Haematology, University Hospital Utrecht, Utrecht, The Netherlands

› Author Affiliations

Abstract

PDF Download

Summary

The effect of sera and purified IgG isolated from plasma of 46 patients with systemic lupus erythematosus (SLE) and 9 healthy donors on the endothelial cell (EC) mediated protein C activation was investigated. Out of the 46 SLE sera used, 19 were antiphospholipid antibodies (aPL) positive. From 12 patients IgG was isolated, of which 6 contained aPL. EC were first incubated with IgG (7 mg/ml) or serum (1: 1 diluted) for 1 h and then tested for their ability to promote protein C activation by thrombin, with the cells either in a monolayer or in a suspension. The normal range (mean of control values ± 2 SD) of protein C activation was 80-120%. In contrast to others, we could not detect an inhibition of protein C activation by any of the patient IgG's or sera.

The recently described cofactor for binding of antiphospholipid antibodies to phospholipids, β₂-glycoprotein I, was purified and added to the purified IgG's. A combination of these two components did not inhibit the EC mediated protein C activation by thrombin.

This study suggests that the inhibition of the protein C activation, mediated by EC, is not a general mechanism by which aPL related thrombosis can be explained.

PDF (1148 kb)

References

References
1 Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GRV. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-4
2 Derksen RHWM, Kater L. Lupus anticoagulant: revival of an old phenomenon. Clin Exp Rheumatol 1985; 3: 349-57
3 Feinstein DI. Lupus anticoagulant, thrombosis and fetal loss. N Engl J Med 1985; 313: 1348-50
4 Derksen RHWM, Bouma BN, Kater L. The striking association between lupus anticoagulant and fetal loss in systemic lupus erythematosus. Arthritis Rheum 1986; 29: 695-6
5 Lechner K, Pabinger-Fasching I. Lupus anticoagulants and thrombosis. Haemostasis 1985; 15: 254-62
6 Galli M, Comfurius P, Maassen C, Hemker HC, De Baets HM, Van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7
7 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: (β₂-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87 (11) 4120-4
8 Derksen RHWM, Hasselaar P, Oosting JD, De Groot PG. The antiphospholipid antibody dilemma. Clin Rheumatol 1990; 9 (No. 1 Suppl. No. 1) 39-44
9 Cariou R, Tobelem G, Bellucci S, Soria J, Soria C, Maclouf J, Caen J. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells – Inhibition of thrombomodulin-dependent protein C activation. Thromb Haemostas 1988; 60 (1) 54-8
10 Freyssinet JM, Wiesel ML, Gauchy J, Boneu B, Cazenave JP. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity – A mechanism for thrombosis. Thromb Haemostas 1986; 55 (3) 309-13
11 Hasselaar P, Derksen RHWM, Blokzijl L, De Groot PG. Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis. Thromb Haemostas 1988; 59: 80-5
12 Comp PC, De Bault LE, Esmon NE, Esmon CP. Human thrombomodulin is inhibited by IgG from two patients with non-specific anticoagulants. Blood 1983; 62: 1099 (Abstract)
13 Francis RB, McGehee WG, Feinstein DI. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis. Thromb Haemostas 1988; 59: 412-4
14 Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78: 2249-52
15 Stenflo J. Structure and function of protein C. Semin Thromb Haemostas 1984; 10: 109-21
16 Van Hinsberg VWM, Bertina RM, Van Wijngaarden A, Van Tilburg NH, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator inhibitor activity in endothelial cell conditioned medium. Blood 1985; 65: 444-51
17 Griffin JH, Evatt B, Zimmermann TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-3
18 Freyssinet JM, Gauchy J, Cazenave JP. The effect of phospholipids on the activation of protein C by the human thrombin-thrombomodulin complex. Biochem J 1986; 238: 151-7
19 Edelhoch H. Spectroscopic determination of tryptophane and tyrosine in proteins. Biochemistry 1967; 6: 1948-54
20 Derksen RHWM, Hasselaar P, Blokzijl L, Gmelig Meyling FHJ, De Groot PG. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis 1988; 47: 364-71
21 Harris EN. The second international anti-cardiolipin standardization workshop/The Kingston anti-phospholipid antibody study (KAPS) group. Am J Clin Pathol 1990; 94: 476-84
22 Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. J Clin Invest 1973; 52: 2745-56
23 Willems C, Astaldi GCB, De Groot PG, Janssen MC, Gonsalves MD, Zeijlemaker WP, Van Mourik JA, Van Aken WG. Media conditioned by cultured human vascular endothelial cells inhibit the growth of vascular smooth muscle cells. Exp Cell Res 1982; 139: 191-7
24 Maciag T, Hoover GA, Stemerman MB, Weinstein R. Serial propagation of human endothelial cells in vitro. J Cell Biol 1981; 91: 420-6
25 Delvos U, Meusel P, Preissner KT, Müller-Berghaus G. Formation of activated protein C and inactivation of cell-bound thrombin by antithrombin III at the surface of cultured vascular endothelial cells – A comparative study of two anticoagulant mechanisms. Thromb Haemostas 1987; 57: 87-91
26 Suzuki K, Kusumoto H, Deyashiki Y, Nishioka J, Maruyama I, Zushi M, Kawahara S, Honda G, Yamamoto S, Horiguchi S. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987; 6: 1891-7
27 Hasselaar P, Derksen RHWM, Oosting JD, Blokzijl L, De Groot PG. Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells. Thromb Haemostas 1989; 62: 654-60
28 Tannenbaum SH, Finko R, Cines DB. Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 1986; 137: 1532-7
29 Rustin MHA, Bull HA, Machin SJ, Isenberg DA, Snaith ML, Dowd PM. Effects of the lupus anticoagulant in patients with systemic lupus erythematosus on endothelial cell prostacyclin release and procoagulant activity. J Invest Dermatol 1988; 90: 744-8
30 Nawroth PP, Stern DM. Modulation of endothelial cell haemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-5
31 Marciniak E, Romond E. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-32
32 Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101-7